Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 41

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

RHOA Is a Modulator of the Cholesterol-Lowering Effects of Statin

Medina, Marisa W., Theusch, Elizabeth, Naidoo, Devesh, Bauzon, Frederick, Stevens, Kristen, Mangravite, Lara M., Kuang, Yu-Lin, Krauss, Ronald M. · 2012 · PLoS Genetics

Abstract

Although statin drugs are generally efficacious for lowering plasma LDL-cholesterol levels, there is considerable variability in response. To identify candidate genes that may contribute to this variation, we used an unbiased genome-wide filter approach that was applied to 10,149 genes expressed in immortalized lymphoblastoid cell lines (LCLs) derived from 480 participants of the Cholesterol and Pharmacogenomics (CAP) clinical trial of simvastatin. The criteria for identification of candidates included genes whose statin-induced changes in expression were correlated with change in expression of HMGCR, a key regulator of cellular cholesterol metabolism and the target of statin inhibition. This analysis yielded 45 genes, from which RHOA was selected for follow-up because it has been found to participate in mediating the pleiotropic but not the lipid-lowering effects of statin treatment. RHOA knock-down in hepatoma cell lines reduced HMGCR, LDLR, and SREBF2 mRNA expression and increased intracellular cholesterol ester content as well as apolipoprotein B (APOB) concentrations in the conditioned media. Furthermore, inter-individual variation in statin-induced RHOA mRNA expression measured in vitro in CAP LCLs was correlated with the changes in plasma total cholesterol, LDL-cholesterol, and APOB induced by simvastatin treatment (40 mg/d for 6 wk) of the individuals from whom these cell lines were derived. Moreover, the minor allele of rs11716445, a SNP located in a novel cryptic RHOA exon, dramatically increased inclusion of the exon in RHOA transcripts during splicing and was associated with a smaller LDL-cholesterol reduction in response to statin treatment in 1,886 participants from the CAP and Pravastatin Inflamation and CRP Evaluation (PRINCE; pravastatin 40 mg/d) statin clinical trials. Thus, an unbiased filter approach based on transcriptome-wide profiling identified RHOA as a gene contributing to variation in LDL-cholesterol response to statin, illustrating the power of this approach for identifying candidate genes involved in drug response phenotypes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pgen.1003058

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Functional validation of RHOA. (A) HMGCR and RHOA levels were quantified in 480 CAP LCLs after 24 hour incubation with 2 µM activated simvastatin or sham buffer. HepG2 (n = 12) and Huh7 cells (n = 6) cells were reverse transfected with Silencer Select siRNAs specific for RHOA or a negative control using the NeoSport transfection reagent. (B) After 48 hours, RHOA transcript levels were quantified by real time qPCR and compared to cells treated with the negative control to calculate percent knock-down of the RHOA transcript. (C) HepG2 cells (n = 2) were transfected and the cell lysate probed by immunoblot with antibodies to RHOA and β-actin. (D) HMGCR, SREBF2, and LDLR transcript levels were quantified by qPCR. APOB and APOAI accumulated in the cell culture media were quantified by ELISA. (E) Total and free intracellular cholesterol levels were quantified using the Amplex Red Cholesterol Assay Kit (Invitrogen), with cholesterol ester calculated as the difference of total minus free cholesterol. (F) HepG2 cells (n = 10) were incubated for 24 hours with 2 µM simvastatin +10% LPDS or sham buffer +10% FBS (control conditions), after which cells were harvested and RHOA and HMGCR mRNA were quantified by qPCR, and RHOA and HMGCR protein were quantified by immunoblot. Band densities were quantified using Alphaview SA version 3.4.0. The dashed line indicates a fold change of 1. (G) One representative immunoblot of HepG2 cells incubated as described in section D. (H) HepG2 and Huh7 cells (n = 6 each cell type) were transfected with the Silencer Select siRNA specific for SREBF1, SREBF2 or a non-targeting negative control. RHOA, HMGCR and CLPTM1 transcript levels were quantified after 48 hours. Statistically significant differences in gene expression, APOB, APOAI and intracellular cholesterol were evaluated by paired two-tailed t-test. All values shown are mean ± standard error. *p<0.05; **p<0.01, ***p<0.001.
Figure 1 Functional validation of RHOA. (A) HMGCR and RHOA levels were quantified in 480 CAP LCLs after 24 hour incubation with 2 µM activated simvastatin or sham buffer. HepG2 (n = 12) and Huh7 cells (n = 6) cells were reverse transfected with Silencer Select siRNAs specific for RHOA or a negative control using the NeoSport transfection reagent. (B) After 48 hours, RHOA transcript levels were quantified by real time qPCR and compared to cells treated with the negative control to calculate percent knock-down of the RHOA transcript. (C) HepG2 cells (n = 2) were transfected and the cell lysate probed by immunoblot with antibodies to RHOA and β-actin. (D) HMGCR, SREBF2, and LDLR transcript levels were quantified by qPCR. APOB and APOAI accumulated in the cell culture media were quantified by ELISA. (E) Total and free intracellular cholesterol levels were quantified using the Amplex Red Cholesterol Assay Kit (Invitrogen), with cholesterol ester calculated as the difference of total minus free cholesterol. (F) HepG2 cells (n = 10) were incubated for 24 hours with 2 µM simvastatin +10% LPDS or sham buffer +10% FBS (control conditions), after which cells were harvested and RHOA and HMGCR mRNA were quantified by qPCR, and RHOA and HMGCR protein were quantified by immunoblot. Band densities were quantified using Alphaview SA version 3.4.0. The dashed line indicates a fold change of 1. (G) One representative immunoblot of HepG2 cells incubated as described in section D. (H) HepG2 and Huh7 cells (n = 6 each cell type) were transfected with the Silencer Select siRNA specific for SREBF1, SREBF2 or a non-targeting negative control. RHOA, HMGCR and CLPTM1 transcript levels were quantified after 48 hours. Statistically significant differences in gene expression, APOB, APOAI and intracellular cholesterol were evaluated by paired two-tailed t-test. All values shown are mean ± standard error. *p<0.05; **p<0.01, ***p<0.001.CC BY · PubMed Central
Figure 2 Association of variation in RHOA mRNA expression levels with other cellular phenotypes. 480 CAP LCLs from Caucasian donors were incubated with 2 µM activated simvastatin or sham buffer for 24 hours, after which genome-wide gene expression was quantified using the Illumina human HT8v3 beadarray, and cell surface LDLR protein was measured by FACS. Greater induction of RHOA transcript levels was positively correlated with greater induction of both LDLR and HMGCR (shown in Figure 1) mRNA (A) and inversely correlated with induction of cell surface LDLR protein (B). Gene expression values and measures of LDLR protein were adjusted for cellular covariates as described in Figure 1, log transformed, the delta calculated as the statin-treated minus the sham-treated value, and quantile normalized.
Figure 2 Association of variation in RHOA mRNA expression levels with other cellular phenotypes. 480 CAP LCLs from Caucasian donors were incubated with 2 µM activated simvastatin or sham buffer for 24 hours, after which genome-wide gene expression was quantified using the Illumina human HT8v3 beadarray, and cell surface LDLR protein was measured by FACS. Greater induction of RHOA transcript levels was positively correlated with greater induction of both LDLR and HMGCR (shown in Figure 1) mRNA (A) and inversely correlated with induction of cell surface LDLR protein (B). Gene expression values and measures of LDLR protein were adjusted for cellular covariates as described in Figure 1, log transformed, the delta calculated as the statin-treated minus the sham-treated value, and quantile normalized.CC BY · PubMed Central
Figure 3 Relationship between RHOA haplotypes H3B and H2 and statin-induced changes in LDL-cholesterol response in the CAP (N = 580) and PRINCE (N = 1306) clinical trials. Linear regression of statin-induced changes (delta log) in LDL-cholesterol with adjustment age, sex, BMI, smoking status, and clinical trial was used to test for association with RHOA haplotypes. Graph depicts mean percent change in LDL-cholesterol +/− SE.
Figure 3 Relationship between RHOA haplotypes H3B and H2 and statin-induced changes in LDL-cholesterol response in the CAP (N = 580) and PRINCE (N = 1306) clinical trials. Linear regression of statin-induced changes (delta log) in LDL-cholesterol with adjustment age, sex, BMI, smoking status, and clinical trial was used to test for association with RHOA haplotypes. Graph depicts mean percent change in LDL-cholesterol +/− SE.CC BY · PubMed Central
Figure 4 Association between RHOA haplotypes and expression of RHOA exon 2.5. (A) RHOA gene structure and location and sequence of exon 2.5. The 5′ and 3′ UTRs are indicated in solid grey, canonical exons are outlined in grey, and the novel exon is shown in red. The location of the three common RHOA exonic SNPs are shown. RNA-Seq libraries were prepared from HepG2, Hep3B, Huh7, and CAP LCLs (n = 3) and sequenced using 100 bp paired-end reads, and the novel exon was discovered by inspecting novel junction spanning reads. (B) Total RHOA expression levels and RHOA exon 2.5 levels were measured using qPCR, the percent containing exon 2.5 were calculated by dividing RHOA exon 2.5 levels by total RHOA levels, adjusted for batch effects using regression, and normal quantile transformed prior to association testing using linear regression. Graphs depict mean +/− SE. (C) CAP LCL cDNAs containing RHOA exon 2.5 were PCR-amplified and Sanger sequenced and the relative amounts of each allele of rs11716445 in exon 2.5 were estimated by measuring the height of the sequencing traces. (D) Representative sequencing traces of the LCL cDNA and genomic DNA of three heterozygous individuals from CAP illustrate that H3B is a cis-acting splicing QTL exhibiting allele-specific expression in RHOA exon 2.5 (rs11716445 and rs2878298) but not exon 5 (rs3448). H3B contains the minor allele [T] of rs11716445, H1 contains the minor allele [G] of rs2878298, and H2 contains the minor allele [A] of rs3448.
Figure 4 Association between RHOA haplotypes and expression of RHOA exon 2.5. (A) RHOA gene structure and location and sequence of exon 2.5. The 5′ and 3′ UTRs are indicated in solid grey, canonical exons are outlined in grey, and the novel exon is shown in red. The location of the three common RHOA exonic SNPs are shown. RNA-Seq libraries were prepared from HepG2, Hep3B, Huh7, and CAP LCLs (n = 3) and sequenced using 100 bp paired-end reads, and the novel exon was discovered by inspecting novel junction spanning reads. (B) Total RHOA expression levels and RHOA exon 2.5 levels were measured using qPCR, the percent containing exon 2.5 were calculated by dividing RHOA exon 2.5 levels by total RHOA levels, adjusted for batch effects using regression, and normal quantile transformed prior to association testing using linear regression. Graphs depict mean +/− SE. (C) CAP LCL cDNAs containing RHOA exon 2.5 were PCR-amplified and Sanger sequenced and the relative amounts of each allele of rs11716445 in exon 2.5 were estimated by measuring the height of the sequencing traces. (D) Representative sequencing traces of the LCL cDNA and genomic DNA of three heterozygous individuals from CAP illustrate that H3B is a cis-acting splicing QTL exhibiting allele-specific expression in RHOA exon 2.5 (rs11716445 and rs2878298) but not exon 5 (rs3448). H3B contains the minor allele [T] of rs11716445, H1 contains the minor allele [G] of rs2878298, and H2 contains the minor allele [A] of rs3448.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 33

  1. D Altshuler, 2008, Genetic mapping in human disease, Science, 322, 881, 10.1126/science.1156409 · DOI · Paper page
  2. CI Amos, 2007, Successful design and conduct of genome-wide association studies, Hum Mol Genet, 16 Spec No. 2, R220, 10.1093/hmg/ddm161 · DOI
  3. JF Thompson, 2009, Comprehensive Whole-Genome and Candidate Gene Analysis for Response to Statin Therapy in the Treating to New Targets (TNT) Cohort, Circulation Cardiovascular Genetics, 2, 173, 10.1161/CIRCGENETICS.108.818062 · DOI · Paper page
  4. Y Tanaka, 2009, Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C, Nat Genet, 41, 1105, 10.1038/ng.449 · DOI · Paper page
  5. DI Chasman, 2012, Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol Reduction: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial, Circ Cardiovasc Genet, 5, 257, 10.1161/CIRCGENETICS.111.961144 · DOI · Paper page
  6. JL Goldstein, 1990, Regulation of the mevalonate pathway, Nature, 343, 425, 10.1038/343425a0 · DOI · Paper page
  7. JL Goldstein, 1985, Receptor-mediated endocytosis: concepts emerging from the LDL receptor system, Annu Rev Cell Biol, 1, 1, 10.1146/annurev.cb.01.110185.000245 · DOI · Paper page
  8. MS Brown, 1985, The LDL receptor and HMG-CoA reductase–two membrane molecules that regulate cholesterol homeostasis, Curr Top Cell Regul, 26, 3, 10.1016/B978-0-12-152826-3.50008-5 · DOI
  9. JA Simon, 2006, Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study, Am J Cardiol, 97, 843, 10.1016/j.amjcard.2005.09.134 · DOI · Paper page
  10. P Guillaumot, 2010, Pdro, a protein associated with late endosomes and lysosomes and implicated in cellular cholesterol homeostasis, PLoS ONE, 5, e10977, 10.1371/journal.pone.0010977 · DOI
  11. K Okuhira, 2010, Binding of PDZ-RhoGEF to ATP-binding cassette transporter A1 (ABCA1) induces cholesterol efflux through RhoA activation and prevention of transporter degradation, J Biol Chem, 285, 16369, 10.1074/jbc.M109.061424 · DOI
  12. DM Altshuler, 2010, Integrating common and rare genetic variation in diverse human populations, Nature, 467, 52, 10.1038/nature09298 · DOI · Paper page
  13. JC Barrett, 2005, Haploview: analysis and visualization of LD and haplotype maps, Bioinformatics, 21, 263, 10.1093/bioinformatics/bth457 · DOI · Paper page
  14. CA Argmann, 2005, Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux, J Biol Chem, 280, 22212, 10.1074/jbc.M502761200 · DOI
  15. DA Corey, 2007, Elevated small GTPase activation influences the cell proliferation signaling control in Niemann-Pick type C fibroblasts, Biochim Biophys Acta, 1772, 748, 10.1016/j.bbadis.2007.03.008 · DOI
  16. D Hoshino, 2009, A novel protein associated with membrane-type 1 matrix metalloproteinase binds p27(kip1) and regulates RhoA activation, actin remodeling, and matrigel invasion, J Biol Chem, 284, 27315, 10.1074/jbc.M109.041400 · DOI
  17. O Oliyarnyk, 2005, Interindividual differences of response to statin treatment cannot be explained by variations of the human gene for RhoA, Biochem Genet, 43, 143, 10.1007/s10528-005-1507-0 · DOI
  18. K Ihara, 1998, Crystal structure of human RhoA in a dominantly active form complexed with a GTP analogue, J Biol Chem, 273, 9656, 10.1074/jbc.273.16.9656 · DOI · Paper page
  19. K Rittinger, 1997, Structure at 1.65 A of RhoA and its GTPase-activating protein in complex with a transition-state analogue, Nature, 389, 758, 10.1038/39651 · DOI · Paper page
  20. PJ Smith, 2006, An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers, Hum Mol Genet, 15, 2490, 10.1093/hmg/ddl171 · DOI · Paper page
  21. S Chandradas, 2010, Antagonistic roles of four SR proteins in the biosynthesis of alternatively spliced tissue factor transcripts in monocytic cells, J Leukoc Biol, 87, 147, 10.1189/jlb.0409252 · doi:10.1189/jlb.0409252
  22. MW Medina, 2008, Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin, Circulation, 118, 355, 10.1161/CIRCULATIONAHA.108.773267 · DOI · Paper page
  23. RP Mason, 2005, Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions, Am J Cardiol, 96, 11F, 10.1016/j.amjcard.2005.06.008 · DOI
  24. MS Brown, 1978, Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase, J Biol Chem, 253, 1121, 10.1016/S0021-9258(17)38120-6 · DOI · Paper page
  25. LM Mangravite, Combined Influence of LDLR and HMGCR Sequence Variation on Lipid-Lowering Response to Simvastatin, Arterioscler Thromb Vasc Biol, 30, 1485, 10.1161/ATVBAHA.110.203273 · DOI · Paper page
  26. VG Tusher, 2001, Significance analysis of microarrays applied to the ionizing radiation response, Proc Natl Acad Sci U S A, 98, 5116, 10.1073/pnas.091062498 · DOI · Paper page
  27. JT Leek, 2008, A general framework for multiple testing dependence, Proc Natl Acad Sci U S A, 105, 18718, 10.1073/pnas.0808709105 · DOI · Paper page
  28. F Innocenti, 2011, Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue, PLoS Genet, 7, e1002078, 10.1371/journal.pgen.1002078 · DOI · Paper page
  29. MW Medina, 2011, Coordinately regulated alternative splicing of genes involved in cholesterol biosynthesis and uptake, PLoS ONE, 6, e19420, 10.1371/journal.pone.0019420 · DOI
  30. M Barber, 2010, Genome-wide association of lipid-lowering response to statins in combined study populations, PLoS ONE, 5, e9763, 10.1371/journal.pone.0009763 · DOI · Paper page
  31. DI Chasman, 2004, Pharmacogenetic study of statin therapy and cholesterol reduction, Jama, 291, 2821, 10.1001/jama.291.23.2821 · DOI · Paper page
  32. AD Johnson, 2008, SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap, Bioinformatics, 24, 2938, 10.1093/bioinformatics/btn564 · DOI · Paper page
  33. L Cartegni, 2003, ESEfinder: A web resource to identify exonic splicing enhancers, Nucleic Acids Res, 31, 3568, 10.1093/nar/gkg616 · DOI · Paper page

Cited by

See all 41

Metadata

Authors
Medina, M. W., Theusch, E., Naidoo, D., Bauzon, F., Stevens, K., Mangravite, L. M., Kuang, Y.-L., & Krauss, R. M.
Venue
PLoS Genetics
Published
2012-11-15
Volume
8
Issue
11
Pages
e1003058
ISSN
1553-7404
Cited by
41
References
1
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: RHOA Is a Modulator of the Cholesterol-Lowering Effects of Statin. https://app.cochat.ai/papers/10.1371/journal.pgen.1003058
The paper
Medina, M. W., Theusch, E., Naidoo, D., Bauzon, F., Stevens, K., Mangravite, L. M., Kuang, Y.-L., & Krauss, R. M. (2012). RHOA Is a Modulator of the Cholesterol-Lowering Effects of Statin. PLoS Genetics. https://doi.org/10.1371/journal.pgen.1003058

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.